{"id":"https://openalex.org/W2189160661","doi":null,"title":"Comparisonof Pharmacokineticsof 5-Fluorouraciland 5-Fluorouracil with ConcurrentThymidine Infusionsin a Phase I Trial1","display_name":"Comparisonof Pharmacokineticsof 5-Fluorouraciland 5-Fluorouracil with ConcurrentThymidine Infusionsin a Phase I Trial1","publication_year":1980,"publication_date":"1980-01-01","ids":{"openalex":"https://openalex.org/W2189160661","mag":"2189160661"},"language":"en","primary_location":{"id":"mag:2189160661","doi":null,"is_oa":false,"landing_page_url":"http://cancerres.aacrjournals.org/content/40/1/107.full.pdf","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null},"volume":null,"type":"article","indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5007239425","display_name":"John M. Kirkwood","orcid":"https://orcid.org/0000-0002-3570-4476","observed_orcids":["https://orcid.org/0000-0002-3570-4476"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"John M. Kirkwood","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-3570-4476","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108533330","display_name":"William D. Ensminger","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"William D. Ensminger","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"A. Rosowsky","orcid":"https://orcid.org/0000-0001-7803-6650","observed_orcids":["https://orcid.org/0000-0001-7803-6650"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. Rosowsky","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-7803-6650","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110011199","display_name":"Nicholas Papathanasopoulos","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"N. PAPATHANASOPOULOS","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":null,"display_name":"E Frei","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"E Frei","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.22307374,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.7416999936103821,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.7416999936103821,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.09120000153779984,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.07829999923706055,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/5-fluorouracil","display_name":"5-fluorouracil","score":0.996999979019165},{"id":"https://openalex.org/keywords/thymidine","display_name":"thymidine","score":0.8709999918937683},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.7590000033378601},{"id":"https://openalex.org/keywords/circulating-half-life","display_name":"serum half-life","score":0.765999972820282},{"id":"https://openalex.org/keywords/biexponential-decay","display_name":"biexponential decay","score":0.7549999952316284},{"id":"https://openalex.org/keywords/continuous-infusion","display_name":"continuous infusion","score":0.6179999709129333},{"id":"https://openalex.org/keywords/methotrexate-toxicity","display_name":"methotrexate toxicity","score":0.7549999952316284},{"id":"https://openalex.org/keywords/drug-toxicity","display_name":"drug toxicity","score":0.6439999938011169},{"id":"https://openalex.org/keywords/mucositis","display_name":"mucositis","score":0.781000018119812},{"id":"https://openalex.org/keywords/myelosuppression","display_name":"myelosuppression","score":0.9980000257492065},{"id":"https://openalex.org/keywords/gastrointestinal-toxicity","display_name":"gastrointestinal toxicity","score":0.9520000219345093},{"id":"https://openalex.org/keywords/fluoropyrimidine","display_name":"fluoropyrimidine","score":0.8799999952316284},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.8230000138282776},{"id":"https://openalex.org/keywords/dna-synthesis-inhibition","display_name":"DNA synthesis inhibition","score":0.5799999833106995},{"id":"https://openalex.org/keywords/rna-synthesis-inhibition","display_name":"RNA synthesis inhibition","score":0.8149999976158142},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.48500001430511475}],"concepts":[{"id":"https://openalex.org/C2780456651","wikidata":"https://www.wikidata.org/wiki/Q238512","display_name":"Fluorouracil","level":3,"score":0.569026529788971},{"id":"https://openalex.org/C44280652","wikidata":"https://www.wikidata.org/wiki/Q104837","display_name":"Phase (matter)","level":2,"score":0.4651876986026764},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.21342775225639343},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.12278333306312561},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.0955457091331482},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.08375674486160278},{"id":"https://openalex.org/C62520636","wikidata":"https://www.wikidata.org/wiki/Q944","display_name":"Quantum mechanics","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:2189160661","doi":null,"is_oa":false,"landing_page_url":"http://cancerres.aacrjournals.org/content/40/1/107.full.pdf","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9763000011444092,"id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":7,"referenced_works":["https://openalex.org/W1479960751","https://openalex.org/W1498359474","https://openalex.org/W1603356295","https://openalex.org/W1972465013","https://openalex.org/W2005789224","https://openalex.org/W2045344972","https://openalex.org/W2430884327"],"related_works":["https://openalex.org/W1581888219","https://openalex.org/W2097606314","https://openalex.org/W2414563438","https://openalex.org/W1854328744","https://openalex.org/W2170726903","https://openalex.org/W1490806706","https://openalex.org/W2397743293","https://openalex.org/W1554789943","https://openalex.org/W2408870256","https://openalex.org/W2067428797","https://openalex.org/W1981721848","https://openalex.org/W2131508432","https://openalex.org/W2615516530","https://openalex.org/W3112012206","https://openalex.org/W1981850385","https://openalex.org/W1998729777"],"abstract_inverted_index":{"ABSTRACTTheserumhalf-lifeof5-fluorouracil(5-FUra)inhumansisbestdescribedasabiexponentialdecayfunction,with12a":[0],"=":[1],"7.8":[2],"\u00b12.6":[3],"(S.E.)":[4],"mm":[5,10],"and":[6],"t112$=":[7],"36.8":[8],"\u00b113.5":[9],"during":[11],"initialcoursesofthisdrugalone.Pharmacokineticsof5-FUraduringcoursesofdailytherapy(for5days)revealedprolongationoft112inbothcomponentsofthedecaycurve,whichhasnotbeenpreviouslyreported.Despitetheefficacyofthymidine(dThd)givenasacontinuousi.v.infusionof8g/sqm/dayinpreventionofhigh-dosemethotrexatetoxicity,continuousinfusionofdThdatthisdosedoesnotpreventthetoxicityof5-FUraorreverseinhibitionofDNAandRNAsynthesisby5-FUra.Onthecontrary,continuousinfusionofdThdappearstoincreasethetoxicityof5-FUrainallrespects.Pharmacokineticstudiesof5-FUraduringcontinuousdThdinfusionrevealedprolongationofthe5-FUra12whichremainedstablethroughthecourseof5daysof5-FUrawithdThd.Thisprotracted12@5believedtoaccountatleastinpartfortheincreasedtoxicityof5-FUrawithdThd.Dose-limitingmucositis,myelosuppression,andgastrointestinaltoxicitywereobservedat5-FUradosesrangingfromone-halftotwo-thirdsthecustomarilytolerateddoseof5-FUraaloneinsimilarcoursesofdailybolustherapy(for5days).INTRODUCTIONThefluoropyrimidineshavehadamajorroleinhumancancerchemotherapysincetheirintroductionmorethanagenerationago.5-FUra4hasbeenthemostwidelyusedfluoropyrimidine,mainlyduetoitslowercostandgreateravailability.Ithasexperimentalantineoplasticactivitycomparabletotheotherfluoropyrimidines(e.g.,5-fluoro-2'-deoxyuridineand5-fluorouridine)atequitoxicdosage.Themechanismofactionof5-FUraisuncertain.Itisprimarilyeffectiveagainstcellsthatareprogressingthroughthecellcycle;cellsinallphasesofthecellcyclearesusceptibletothecytotoxiceffectsof5-FUra(4,9,10,14).Theantimetabolicactionof5-FUraagainstsomecellsincultureismitigatedbyconcurrentpresenceofdThd(24)oruridine(25).However,theearliestdescribedeffectsofdThdinvivawerefluoropyrimidmnepotentiationinmurinesystems(5).Morerecently,Nayacketa!.(19)havereportedthattheefficacyof5-FUraagainstspontaneousmurinemammaryandcoloncarcinomacanbeimprovedwhenimmediatelyprecededbybolusdosesofdThd.Invivaexperimentssuggesta":[12]},"counts_by_year":[],"updated_date":"2026-10-12T09:40:04.860316","created_date":"2025-10-10T00:00:00"}